Regeneron’s COVID-19 antibody therapy shows promise in hospitalized patients

0
80
FILE PHOTO: An employee works in a lab at the Regeneron Pharmaceuticals Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid

 (Reuters) – Regeneron Pharmaceuticals Inc said on Tuesday initial data from an ongoing study of its experimental antibody cocktail for use in hospitalized COVID-19 patients requiring low-flow oxygen show the therapy was sufficiently effective to warrant continuing the trial.

The drugmaker said in September the cocktail, a combination of two antibodies casirivimab and imdevimab, reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients.

Study participants included those who had produced their own antibodies (seropositive) and those who had not (seronegative).

Seronegative patients treated with the antibody cocktail had a lower risk of death or needing mechanical ventilation, the company said. (http://bit.ly/3pA1AsI)

Based on these results, the company said an ongoing late-stage study in hospitalized patients will continue.

The U.S. Food and Drug Administration last month issued emergency use authorization for the antibody therapy for use in mild to moderate COVID-19 patients who are not currently hospitalized.